Learn how to plan individualized treatments with oral selective estrogen receptor degraders SERDs for patients with HRHER2 breast cancer progressing after endocrine therapy the value of screening for ESR1 mutations and manage toxicities associated with oral SERD therapy in this ondemand webcast
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/activities/oncology/er-mutation-screening/29332-71026/info
- Start Date: 2024-12-31 06:00:00
- End Date: 2024-12-31 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- MOC Credit Details: ABIM - 1.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 125000.0 - Is Kind Support: False Source: Lilly (Any division) - Amount: 38255.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest